SWOT Analysis for ClearPoint Neuro Inc

Price crossing above SMA20 today, and greater than SMA5
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
Companies with Low Debt
Companies with reducing Debt
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
High Volume, High Gain
Top Gainers
Stocks in uptrend most likely to cross above SMA-200 soon
Stock with Low PE (PE < = 10)
Volume Shockers
High Volume, High Gain
Highest Recovery from 52 Week Low

Momentum Trap (DVM)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Risky Value (DVM)
Low durability companies
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
Declining profits every quarter for the past 3 quarters
Stocks Underperforming their Industry Price Change in the Quarter